Qlife Holding Ab · OMXSTO:QLIFE
Qlife Holding Ab — Investor Presentation (December 2021)
25 slides from Qlife Holding Ab's investor presentation, December 2021
Slide 1: Making clinical-grade biomarker data easily and quickly accessible
MAKING CLINICAL- GRADE BIOMARKER DATA EASILY AND QUICKLY ACCESSIBLE. 1
Slide 2: Trends
TRENDS Healthcare Chronic diseases and Growing health decentralisation increase in ageing interest population 2
Slide 3: Say hello to Egoo
11 cm SAY HELLO TO EGOO A mobile test unit with disposable capsules and smart software for personalised diagnostics 3
Slide 4: How it works
HOW IT WORKS Easy sampling with a Advanced optics Raw data is The app mouth swab or a measures transferred to the synchronizes all droplet of blood DNA/RNA/Protein cloud for immediate data and delivers biomarkers analysis the results 4
Slide 5: "I have diabetes type II"
“I HAVE DIABETES TYPE II” Kaj, 76
Slide 6: "My mom says I have PHE"
“MY MOM SAYS I HAVE PHE” Gunnar, 2
Slide 7: "I want to improve my performance"
“I WANT TO IMPROVE MY PERFORMANCE” Christopher, 27
Slide 8: "I am stressed out"
“I AM STRESSED OUT” Olivia, 19
Slide 9: Important questions
IMPORTANT QUESTIONS 9
Slide 10: What has Qlife been focused on the past 12 months?
WHAT HAS >Bringing COVID PCR capsule to market QLIFE BEEN >COVID sales +35 MSEK >Technical dossier for Egoo.Health platform FOCUSED ON (foundation for the platform) >Regulatory requirements (IVDR) THE PAST 12 >Software domentation (heavy) >Production validation (heavy) MONTHS? 10
Slide 11: What are the development steps the next 12 months?
WHAT ARE >CE-Protocols, validation and clinical trials CRP and THE PKU >Pilot productions (12.000 capsules per test to CE- DEVELOPMEN mark) >Upgrade technical dossier T STEPS THE >IVDR submission (6 months) >Market launch NEXT 12 >R&D start on next biomarker MONTHS? 11
Slide 12: When will Qlife have an approved home-use test?
WHEN WILL QLIFE HAVE >CRP = Oct 2022 – Mar 2023 AN APPROVED >PKU = Dec 2022 – May 2023 HOME-USE TEST? 12
Slide 13: How many biomarkers will Qlife launch over the next 5 years?
HOW MANY BIOMARKERS >IMPORTANT: Fundamental platform approved WILL QLIFE >Realistical target 1-2 biomarkers/ per 18 months >5 years plan approx = 5-10 biomarkers approved for LAUNCH OVER home-use >Investigating biomarker matrix THE NEXT 5 YEARS? 13
Slide 14: What about COVID PCR home-use test?
WHAT ABOUT >New market demand may open business case again – we are following opportunities as they COVID PCR arise HOME-USE >Prioritise our resources >Possibility for gaining external financing to TEST? continue 14
Slide 15: Production volumes 2021
PRODUCTION VOLUMES 2021 STEADY INCREASE AND QUALITY INCREASE Units Product Q1 Q2 Q3 Q4 Device / Target Capsule 150 / 10.000 200 / 15.000 300 / 25.000 600 / 40.000 Actual Device 80 100 150 250 Actual Capsule 8.000 12.000 20.000 40.000 >Production output to sustain sales and internal studies >Higher t
Slide 16: Capsule 3-year production plan
CAPSULE 3- 1. Current capsule production line is optimized to output of 20.000/month JANUARY YEAR 2. Current capsule production line replicates and 2-ways shifts PLANNED PRODUCTION Q1 22 3. Adding semi-auto functionalities upstart PLAN in new facility (cannot start in current facilities) to reach 15
Slide 17: Device 3-year production plan
DEVICE 3-YEAR PRODUCTION PLAN OUTSOURCED TO CONTRACT PARTNER >Expected to reach phase 5 in 2022 17
Slide 18: Cooperation Aidian?
COOPERATION AIDIAN? >Status? >Can Qlife cancel the agreement if Aidian doesn’t reach the sales goal? >Which markets are you present in via Aidian today? Which are the most important markets? >Which clients and channels are Aidian focused on 18
Slide 19: How do Qlife see the market for home-use blood testing develop?
HOW DO QLIFE SEE THE MARKET FOR >Many reports point in that direction HOME-USE >However, IVDR has made it more difficult BLOOD >QLIFE is in a good position to become a firstmover TESTING DEVELOP? 19
Slide 20: The upscaling journey
THE UPSCALING 1. PRODUCT READINESS JOURNEY 2. BUILD-UP CLINICAL SALES 3. MARKET-LEADING POSITION IN PKU GLOBALLY 4. PAVE THE WAY TO CONSUMER HEALTH CE-mark of core Covid-19 PCR Build KOL customer base: virus biomarker test Hospitals, institutions, REVENUE speciality fields Establish presence as Prov
Slide 21: Progress on IP?
PROGRESS ON IP? >Danish Patent no. DK180348B1 issued. >PCT/EP2020/087510 filed on 21 December 2020 (under examination). >Danish Patent application no. PA 2019 01565. >PCT/EP2020/087539 filed on 21 December 2020 (under examination). >Worldwide protection 21
Slide 22: Is Qlife involved in COVID laboratory testing?
IS QLIFE INVIOLVED IN >Not focused on laboratory testing anymore COVID >Laboratory testing has helped to build an agile company LABORATORY >Transition to Egoo.health TESTING? 22
Slide 23: Revenue transition
REVENUE TRANSITION 2021 2021 2021 2021 Revenue kSEK Q1 Q2 Q3 Q4 Revenue 11.176 10.482 5.871 ? >Dip in revenue due to transition >Q1 – Q2 Laboratory sales >Q3 Egoo.health platform sales >Q4 Strong – and only - focus on platform sales 23
Slide 24: Qlife summary
>IVDD to IVDR shift has taken focus and resources QLIFE >Foundation for the future establised SUMMARY >Transition from laboratory to Egoo.health DONE >Company well positioned to be FIRST MOVER 24
Slide 25: Thank you!
THANK YOU! 25
Qlife Holding — Investor Presentation (December 2021) on 6ix